Ipamorelin vs Hexarelin
Verdict: Hexarelin is the strongest GH secretagogue per microgram in common use — and the least forgiving. It desensitizes its own receptor within weeks of continuous use and measurably bumps cortisol and prolactin. Ipamorelin releases less GH per shot but does it silently and sustainably, cycle after cycle. Unless a protocol has a specific, short-term reason to want maximum pulse amplitude (some research interest centers on hexarelin's cardiac effects), ipamorelin is the rational default.
Side by side
| Ipamorelin | Hexarelin | |
|---|---|---|
| Typical dose | 200 mcg–300 mcg | 100 mcg–200 mcg |
| Frequency | 1–3x daily, often before bed | 1–3x daily |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 5 mg, 10 mg | 2 mg, 5 mg |
| Typical mix | 5 mg + 2 ml water | 5 mg + 2 ml water |
| Units for typical dose | 12 units (300 mcg) | 4 units (100 mcg) |
The desensitization problem
Hexarelin's receptor downregulation is well documented: GH response fades noticeably after 2–4 weeks of daily use, which is why protocols run it in short bursts with equal-length breaks. Ipamorelin shows minimal tachyphylaxis at standard doses — the practical meaning is that ipamorelin's 'weaker' pulse is still there in month three, when hexarelin's stronger one may not be.
The cardiac footnote
Hexarelin uniquely shows cardioprotective signals in animal models — effects on cardiac fibrosis and function that appear partly independent of GH release, likely via CD36 binding. This keeps it scientifically interesting even as it loses the bodybuilding market to ipamorelin.
Dosing
Both dose 100–200 mcg per injection, one to three times daily. Hexarelin protocols hard-cap cycle length (commonly 4 weeks on, 4 off); ipamorelin tolerates longer runs. Both pair with a GHRH analog for synergy.
Can you stack them?
Choose one secretagogue per protocol. Either pairs with CJC-1295 (no DAC); hexarelin's short cycles just mean the stack rotates more often.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.